Protocol Ledger

NCT07340320 · Phase II · RECRUITING

A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

Interventional Phase II clinical trial protocol NCT07340320 sponsored by Corxel Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-06 Enrollment: 240 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07340320
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07340320
Protocol FieldVerified Registry Value
NCT IdentifierNCT07340320
Consolidated Lead SponsorCorxel Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment240 participants (ESTIMATED)
Registered Start Date2026-02-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07340320
Hospital Research SiteLocationSite Profile
Tampa General HospitalTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI